{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T12:19:06Z","timestamp":1775996346592,"version":"3.50.1"},"reference-count":115,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>An adequate blood supply is essential for cancer cells to survive and grow; thus, the concept of inhibiting tumor angiogenesis has been applied to cancer therapy, and several drugs are already in clinical use. It has been shown that treatment with those anti-angiogenic drugs improved the response rate and prolonged the survival of patients with various types of cancer; however, it is also true that the effect was mostly limited. Currently, the disappointing clinical results are explained by the existence of intrinsic or acquired resistance to the therapy mediated by both tumor cells and stromal cells. This article reviews the mechanisms of resistance mediated by stromal cells such as endothelial cells, pericytes, fibroblasts and myeloid cells, with an emphasis on fibrocytes, which were recently identified as the cell type responsible for regulating acquired resistance to anti-angiogenic therapy. In addition, the other emerging role of fibrocytes as mediator-producing cells in tumor progression is discussed.<\/jats:p>","DOI":"10.3390\/ijms19010098","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T10:58:47Z","timestamp":1514545127000},"page":"98","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression"],"prefix":"10.3390","volume":"19","author":[{"given":"Hisatsugu","family":"Goto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10456-016-9496-7","article-title":"John Hunter and the origin of the term \u2018\u2018angiogenesis\u201d","volume":"19","author":"Lenzi","year":"2016","journal-title":"Angiogenesis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-4899-2444-5_34","article-title":"Control of angiogenesis by heparin and other sulfated polysaccharides","volume":"313","author":"Folkman","year":"1992","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: New concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0031-6997(24)01448-0","article-title":"Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation","volume":"52","author":"Griffioen","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angio-genesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","article-title":"Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents","volume":"13","author":"Kerbel","year":"1991","journal-title":"Bioessays"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: Current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2012.64","article-title":"Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia","volume":"9","author":"Rapisarada","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMe1113368","article-title":"Fighting fire with fire: Rekindling the bevacizumab debate","volume":"366","author":"Montero","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1158\/1078-0432.CCR-07-5287","article-title":"Pathways mediating resistance to vascular endothelial growth factor-targeted therapy","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2016.02.002","article-title":"Role of the tumor stroma in resistance to anti-angiogenic therapy","volume":"25","author":"Huijbers","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies\u2014A review","volume":"8","author":"Alamoudi","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.2174\/138161207782794121","article-title":"Identification of novel drug targets for angiostatic cancer therapy: It takes two to tango","volume":"13","author":"Thijssen","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.1158\/0008-5472.CAN-05-2468","article-title":"Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia","volume":"65","author":"Hillen","year":"2005","journal-title":"Cancer Res."},{"key":"ref_20","first-page":"18","article-title":"Signalling pathways in vasculogenic mimicry","volume":"1806","author":"Paulis","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.neo.7900102","article-title":"Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption","volume":"2","author":"Rubenstein","year":"2000","journal-title":"Neoplasia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-04-0823","article-title":"Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option","volume":"10","author":"Leenders","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1038\/cddis.2012.30","article-title":"Imidazoacridinone-dependent lysosomal photodestruction: A pharmacological Trojan horse approach to eradicate multidrug-resistant cancers","volume":"3","author":"Adar","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","article-title":"Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance","volume":"6","author":"Zhitomirsky","year":"2015","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1038\/cddis.2015.4","article-title":"Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition","volume":"6","author":"Weiss","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","article-title":"Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth","volume":"153","author":"Cheng","year":"2013","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape: The hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"Huijbers","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ajpath.2011.11.029","article-title":"Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment","volume":"180","author":"Akiyama","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_33","first-page":"2249","article-title":"Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib","volume":"7","author":"Huang","year":"2014","journal-title":"Oncol. Target Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","article-title":"Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors","volume":"156","author":"Croci","year":"2014","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09624","article-title":"Glioblastoma stem-like cells give rise to tumour endothelium","volume":"468","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0040-8166(86)90026-1","article-title":"The pericyte\u2014A review","volume":"18","author":"Sims","year":"1986","journal-title":"Tissue Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1083\/jcb.153.3.543","article-title":"Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis","volume":"153","author":"Gerhardt","year":"2001","journal-title":"J. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-540-78281-0_7","article-title":"PDGF and vessel maturation","volume":"180","author":"Hellberg","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"46668","DOI":"10.18632\/oncotarget.8694","article-title":"Tumor refractoriness to anti-VEGF therapy","volume":"7","author":"Ribatti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1083\/jcb.105.3.1455","article-title":"Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells","volume":"105","author":"Orlidge","year":"1987","journal-title":"J. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-016-0740-2","article-title":"Tumor-associated stromal cells as key contributors to the tumor microenvironment","volume":"18","author":"Bussard","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI42405","article-title":"Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma","volume":"121","author":"Cascone","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s004280100458","article-title":"Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma","volume":"440","author":"Valkovic","year":"2002","journal-title":"Virchows Arch."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12307-012-0106-y","article-title":"Role of bone marrow-derived cells in angiogenesis: Focus on macrophages and pericytes","volume":"5","author":"Ding","year":"2012","journal-title":"Cancer Microenviron."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.humimm.2009.02.008","article-title":"Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation","volume":"70","author":"Mantovani","year":"2009","journal-title":"Hum. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1161\/ATVBAHA.113.300168","article-title":"Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: Lessons and open questions","volume":"33","author":"Mantovani","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3390\/ijms18071545","article-title":"Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing","volume":"18","author":"Hesketh","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-54090-0_1","article-title":"Evolutionary Aspects of Macrophages Polarization","volume":"62","author":"Edholm","year":"2017","journal-title":"Results Probl. Cell Differ."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1189\/jlb.0905495","article-title":"Monocyte\/macrophage infiltration in tumors: Modulators of angiogenesis","volume":"80","author":"Dirkx","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: In vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_53","first-page":"527","article-title":"Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration","volume":"63","author":"Hotchkiss","year":"2002","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/94.15.1134","article-title":"Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice","volume":"94","author":"Huang","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2009-01-200931","article-title":"A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood \u201cresident\u201d monocytes, and embryonic macrophages suggests common functions and developmental relationships","volume":"114","author":"Pucci","year":"2009","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1158\/0008-5472.CAN-07-1684","article-title":"Tie2-expressing monocytes and tumor angiogenesis: Regulation by hypoxia and angiopoietin-2","volume":"67","author":"Lewis","year":"2007","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.18632\/oncotarget.1893","article-title":"Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes","volume":"5","author":"Gabrusiewicz","year":"2014","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Safarzadeh, E., Orangi, M., Mohammadi, H., Babaie, F., and Baradaran, B. (2017). Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. J. Cell. Physiol.","DOI":"10.1002\/jcp.26075"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.4049\/jimmunol.177.7.4763","article-title":"TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs","volume":"177","author":"Ezernitchi","year":"2006","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","article-title":"Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients","volume":"61","author":"Filipazzi","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000358640","article-title":"Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model","volume":"33","author":"Liu","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/0008-5472.CAN-15-1021","article-title":"Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells","volume":"75","author":"Rajapaksa","year":"2015","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s13277-015-4477-9","article-title":"The immunobiology of myeloid-derived suppressor cells in cancer","volume":"37","author":"Motallebnezhad","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nbt1323","article-title":"Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells","volume":"25","author":"Shojaei","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nature06348","article-title":"Bv8 regulates myeloid-cell-dependent tumour angiogenesis","volume":"450","author":"Shojaei","year":"2007","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2013.02.007","article-title":"The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins?","volume":"23","author":"Brandau","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/icb.2013.29","article-title":"Myeloid-derived suppressor cells in cancer: Recent progress and prospects","volume":"91","author":"Khaled","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.4161\/cc.8.10.8557","article-title":"On the origin of cancer-associated fibroblasts","volume":"8","author":"Anderberg","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_75","first-page":"482","article-title":"Cancer associated fibroblasts: The dark side of the coin","volume":"1","author":"Cirri","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2015.02.018","article-title":"Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression","volume":"361","author":"Luo","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/ERC-14-0161","article-title":"Tumour-associated fibroblasts contribute to neoangiogenesis in human parathyroid neoplasia","volume":"22","author":"Verdelli","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tips.2009.09.004","article-title":"Tumor and stromal pathways mediating refractoriness\/resistance to anti-angiogenic therapies","volume":"30","author":"Crawford","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/stem.1556","article-title":"CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment","volume":"32","author":"Kinugasa","year":"2014","journal-title":"Stem Cells"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nm.3291","article-title":"An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy","volume":"19","author":"Chung","year":"2013","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-07-0847","article-title":"Platelets take up the monoclonal antibody bevacizumab","volume":"13","author":"Verheul","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_83","first-page":"771","article-title":"Sunitinib is taken up by platelets and inhibits their function","volume":"17","author":"Sabrkhany","year":"2014","journal-title":"Angiogenesis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1387\/ijdb.103228jl","article-title":"Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells","volume":"55","author":"Laurent","year":"2011","journal-title":"Int. J. Dev. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","article-title":"Eosinophils and cancer","volume":"2","author":"Davis","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.2353\/ajpath.2010.090786","article-title":"Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors","volume":"176","author":"Coffelt","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.03.031","article-title":"Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis","volume":"269","author":"Crivellato","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1541-7786.MCR-07-0391","article-title":"Transcriptome of hypoxic immature dendritic cells: Modulation of chemokine\/receptor expression","volume":"6","author":"Ricciardi","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1038\/ncomms9792","article-title":"Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nri2990","article-title":"Fibrocytes: Emerging effector cells in chronic inflammation","volume":"11","author":"Reilkoff","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Pilling, D., Fan, T., Huang, D., Kaul, B., and Gomer, R.H. (2009). Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007475"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1096\/fj.01-0049com","article-title":"Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo","volume":"15","author":"Hartlapp","year":"2001","journal-title":"FASEB J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/labinvest.3700654","article-title":"The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses","volume":"87","author":"Bellini","year":"2007","journal-title":"Lab. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.160.1.419","article-title":"Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes","volume":"160","author":"Chesney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1189\/jlb.0906587","article-title":"Fibrocytes in lung disease","volume":"82","author":"Gomperts","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00072311","article-title":"Circulating fibrocytes are increased in children and young adults with pulmonary hypertension","volume":"39","author":"Yeager","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200710-1557OC","article-title":"Increased circulating fibrocytes in asthma with chronic airflow obstruction","volume":"178","author":"Wang","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_100","first-page":"114","article-title":"Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes","volume":"27","author":"Medbury","year":"2008","journal-title":"Int. Angiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/labinvest.2010.73","article-title":"Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype","volume":"90","author":"Mathai","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/art.34589","article-title":"Circulating fibrocytes contribute to the pathogenesis of collagen antibody-induced arthritis","volume":"64","author":"Galligan","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2012-08-449413","article-title":"Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1172\/JCI44562","article-title":"TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice","volume":"121","author":"Welford","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nm1075","article-title":"Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1","volume":"10","author":"Ceradini","year":"2004","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","article-title":"Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity","volume":"18","author":"Sato","year":"2017","journal-title":"Respir. Res."},{"key":"ref_109","unstructured":"Saijo, A., and Goto, H. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. in preparation."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1078-0432.CCR-07-1154","article-title":"Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group study","volume":"14","author":"Dowlati","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1158\/1078-0432.CCR-08-2917","article-title":"A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic biomarkers","volume":"15","author":"Baar","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2011.85","article-title":"Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer","volume":"104","author":"Loupakis","year":"2011","journal-title":"Br. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/98\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:56:00Z","timestamp":1760208960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["ijms19010098"],"URL":"https:\/\/doi.org\/10.3390\/ijms19010098","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,29]]}}}